Abstract
All the pharmaceutical companies on the globe are working towards creating niche and complex products through investments in R&D. “Indian pharmaceutical companies are always investing a very low amount of their revenue in the R&D work.” Is this statement a myth or a fact? The main aim of this study is to search answer to this relevant question, which directly linked with the growth and survival of the Indian pharmaceutical industry. With the help of revenue and expenditure data of Indian and multinational pharmaceutical companies, this study is an attempt to find an appropriate answer to this question. With special reference to Dr. Reddy's Laboratory Ltd. (a leading Indian pharmaceutical company) and Pfizer Inc. (US based, leading multinational pharmaceutical company), this study also tries to find out the variation of the R&D expenditure made by Indian pharmaceutical companies and multinational pharmaceutical companies. By application of Ratio Analysis, CAGR, T-Test and F-Test this study focuses on analysis of R&D spending of Indian and multinational pharmaceutical companies and to also find out major factors responsible for variation to reach at any conclusion.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: ACADEMICIA: An International Multidisciplinary Research Journal
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
